Premium
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target
Author(s) -
Shi John,
Bodo Juraj,
Zhao Xiaoxian,
Durkin Lisa,
Goyal Tanu,
Meyerson Howard,
Hsi Eric D.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15393
Subject(s) - plasmablastic lymphoma , lymphoma , anaplastic lymphoma kinase , medicine , plasma cell neoplasm , immunophenotyping , cancer research , multiple myeloma , antibody dependent cell mediated cytotoxicity , immunology , pathology , oncology , antibody , plasmacytoma , monoclonal antibody , antigen , lung cancer , malignant pleural effusion